Congress Materials – American Urology Association (AUA 2025)
2025 American Urology Association | Apr 26-29 | Las Vegas, NV
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Healthcare burden associated with cystectomy and trimodal therapy among patients with muscle invasive bladder cancer in the United States
Arlene O. Siefker-Radtke, Mukul Singhal, Kruti Joshi, Bruno Emond, Anabelle Tardif-Samson, Carmine Rossi, Dominic Pilon, Lorie Ellis
Homologous recombination repair mutations, nextgeneration sequencing testing, and time-to-next-treatment by race among patients with metastatic castration-sensitive prostate cancer
Mehmet A. Bilen, Heather H. Cheng, Sabree Burbage, Ibrahim Khilfeh, Carmine Rossi, Lilian Diaz, Yuxi Wang, Gordon Wong, Dominic Pilon, Gordon Brown, Neal Shore, Benjamin Lowentritt, Daniel W. Lin
MoonRISe-1: Phase 3 Study of TAR-210, an Intravesical Erdafitinib Releasing System, Versus Intravesical Chemotherapy in Patients With FGFR-altered Intermediate-risk Non–muscle-invasive Bladder Cancer
Roger Li, Gautam Jayram, Angela Girvin, Jiao Song, Nicole Stone, Cateau Van Oevelen, Jose M Calderon, Lauren Crow, Neil Beeharry, Spyros Triantos, Benjamin Pradere
Outcomes, Healthcare Resource Utilization and Costs of Patients Receiving Definitive Versus Non-Definitive Treatment for Muscle-Invasive Bladder Cancer: a Real-World Analysis within the Veterans Affairs System
Renning Zheng, Jaruda Ithisuphalap, Bolan Linghu, Eleanor O. Caplan, Kirk A Keegan, Sydney A. McIntire, Joshua A. Parrish, Claire Evans, Amanda M. De Hoedt, Sanjay Das, Ariel B. Bourla, Sabine Brookman-May, Hussein Sweiti, Joel Greshock, Stephen J. Freedland, Stephen B. Williams, Anirban P. Mitra
Phase 3 Study of TAR-210 (Intravesical Erdafitinib Releasing System) vs Intravesical Chemotherapy in Patients With BCG–treated High-risk Non–muscle-invasive Bladder Cancer
Neal D Shore, Wolfgang Jessner, Maarten Schuit, Spyros Triantos, Nicole L Stone, Sydney Akapame, Hussein Sweiti, Félix Guerrero-Ramos
Real-world comparison of prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide
Benjamin Lowentritt, Shawn Du, Ibrahim Khilfeh, Dominic Pilon, Sabree Burbage, Carmine Rossi, Frederic Kinkead; Lilian Diaz, Gordon Brown
Real-world time-to-next-treatment and time-to-castration-resistance among patients with metastatic castration-sensitive prostate cancer using androgen-receptor pathway inhibitors with and without homologous recombination repair mutations
Daniel W. Lin, Sabree Burbage, Carmine Rossi, Ibrahim Khilfeh, Lilian Diaz, Yuxi Wang, Dominic Pilon, Gordon Brown, Neal Shore, Benjamin Lowentritt, Heather H. Cheng, Mehmet A. Bilen
Real-world treatment patterns and clinical outcomes in Bacillus Calmette-Guérin (BCG)-experienced or BCG-unresponsive patients with papillary-only high-risk non–muscle-invasive bladder cancer (HR NMIBC)
Girish S. Kulkarni, Sarah Cote, Michael Kelleher, Xin Yin, Dee Lin, Stephen B. Williams
SunRISe-5: A Phase 3, Randomized, Open-Label Study of TAR-200 Compared With Intravesical Chemotherapy After Bacillus Calmette-Guérin in Recurrent High-Risk Non–Muscle-Invasive Bladder Cancer
Sima Porten, Sumeet Bhanvadia, Saltanat Najmi, Hussein Sweiti, John Maffeo, Katharine Stromberg, Jovita Gale, Benjamin Pradere
TAR-200 Monotherapy in Patients With Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer Carcinoma in Situ: 1-Year Durability and Patient-Reported Outcomes From SunRISe-1
Joseph M Jacob, Félix Guerrero-Ramos, Andrea Necchi, Martin Bögemann, Michiel S Van der Heijden, Daniel Zainfeld, Philipp Spiegelhalder, Giuseppe Simone, Evanguelos Xylinas, David Cahn, Yair Lotan, Katie S Murray, Takashi Kawahara, Katharine Stromberg, Jason Martin, Abhijit Shukla, Kristi Bertzos, Shalaka Hampras, Hussein Sweiti, Siamak Daneshmand
TAR-200 Monotherapy in Patients With Bacillus Calmette-Guérin–Unresponsive Papillary Disease–Only High-Risk Non–Muscle-Invasive Bladder Cancer: First Results From Cohort 4 of SunRISe-1
Félix Guerrero-Ramos, Joseph M Jacob, Michiel S Van der Heijden, Martin Bögemann, Siamak Daneshmand, Andrea Necchi, Daniel Zainfeld, Philipp Spiegelhalder, Evanguelos Xylinas, David Cahn, Yair Lotan, Katie S Murray, Takashi Kawahara, Katharine Stromberg, Jason Martin, Abhijit Shukla, Christopher J Cutie, Shalaka Hampras, Hussein Sweiti, Giuseppe Simone
Treatment Patterns and Clinical Outcomes in Patients with Bacillus Calmette-Guérin (BCG)-unresponsive High-risk Non-muscle Invasive Bladder Cancer with Carcinoma in Situ
Stephen B. Williams, Xin Yin, Sarah Cote, Michael Kelleher, Dee Lin, Girish S. Kulkarni
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.